The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025. The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.
The number of undetected HCV-infected persons has been extrapolated to 75,000 according to the results of a 2014 study. Screening efforts have been set up in groups of people said to be at high viral risk: drug users, prisoners, precarious persons or migrants from highly endemic countries. Nevertheless, the concept of universal screening has not yet been adopted by the guardians and the Ministry. It is in this context that "hepatitis free hospital" projects have been carried out in several French cities such as Nice, Nancy and Marseille. The aim of the HOSPI-VHC study is to evaluate the feasibility and efficiency of systematic HCV screening in all medical and surgical departments of 4 National Association of Hepato-Gastroenterologists of General Hospitals (ANGH) hospitals. This pilot project is part of a public health screening program. It will evaluate the interest and usefulness of implementing universal screening in hospitalized patients without taking into account the existence of viral risk factors. This study will also make it possible to evaluate the implementation of a dedicated care pathway: number of patients screened, number of patients referred for consultation and number of patients accepting the consultation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
2,500
Hepatitis C Screening
CHI Créteil
Créteil, France
Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée
Jossigny, France
CH Meaux
Meaux, France
CHIV
Villeneuve-Saint-Georges, France
potential patient versus
Number of HCV serologies collected compared to the number of patients meeting the inclusion criteria during the study period.
Time frame: 7 days
HCV positive
Percentage positive for HCV
Time frame: 7 days
Follow-up
Percentage of patients referred for consultation if HCV positive
Time frame: 2 months
Polymerase chain reaction (PCR)
Percentage of HCV PCR positive patients
Time frame: 7 days
Viral risk factor
Percentage of patients with a viral risk factor
Time frame: 7 days
hepatic fibrosis
Percentage of patients with hepatic fibrosis
Time frame: 7 days
treatment initiation
Percentage of patients benefiting from treatment initiation
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.